A 12% Pure Vitamin C Serum Was Tested on Every Phototype: What the Trial Actually Measured

Vitamin C trials rarely recruit much beyond lighter skin tones, which is what makes a study published in the journal Dermatology and Therapy worth reading. Forty-nine women covering phototypes I through VI applied a dermocosmetic serum containing 12 percent pure vitamin C twice a day for 84 days.

The headline measurement is structural rather than cosmetic. Epidermal thickness rose by 16.4 percent against each participant's own starting point. More than half the group showed improved collagen scores, and the researchers also recorded gains in firmness and elasticity. No treatment-related adverse events occurred over the twelve weeks.

Two things are worth holding onto before reading that as proof. The abstract describes a single-arm design: everyone received the active serum, and no vehicle or untreated comparison group is reported. Skin measured against its own baseline will usually look better after three months of twice-daily application and the attention that comes with being in a study, so not all of the movement can be laid at vitamin C's door.

The second is who ran it. The author disclosures list ties to cosmetic companies including L'Oreal, La Roche-Posay and Galderma. That is ordinary for dermocosmetic research and does not make the measurements wrong, but it is context a reader is entitled to. The serum itself is never named in the abstract, only described by its concentration, so it cannot be matched to a specific bottle on a shelf.

What the study does add is coverage. Instrumented readings of epidermal thickness and collagen organisation across the full Fitzpatrick range are genuinely uncommon in this category, and the absence of adverse events in darker phototypes is useful where irritation and post-inflammatory marking are real concerns.

The paper carries a September 2026 issue date and went online ahead of print in July.